Gastrointestinal hemorrhage
Drug research and approvals for gastrointestinal hemorrhage: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 98 studies of gastrointestinal hemorrhage are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 98
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Development of dEep EndometrioSis Following Acute haemoPerITonEumNCT07944560 · Not reported · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Apr 30, 2026
- Prospective, Multicenter, Randomized Controlled Phase III Trial of Biological Mesh for Alimentary Tract Reconstruction…NCT07921732 · Not applicable · Nanfang Hospital, Southern Medical University · starts May 6, 2026
- Treatment Outcomes and Predictors After Endovascular Intervention for Portal Hypertension-Related Gastrointestinal…NCT07918378 · Not reported · University Medical Center Ho Chi Minh City (UMC) · starts Oct 1, 2026
- Detection of Blood in the GI Lumen With HemoPill AcuteNCT07868068 · Not applicable · Stony Brook University · starts Oct 1, 2026
- Deep Neuromuscular Blockade and a Low-Residue Diet for the Surgical Field in vNOTES HysterectomyNCT07730970 · Not applicable · Fatih Sultan Mehmet Training and Research Hospital · starts Jul 1, 2026
- Tegoprazan Versus Lansoprazole for Endoscopic Ulcer Healing in Bleeding Peptic UlcersNCT07708545 · Phase 2 · Universitas Indonesia · starts Aug 6, 2026
- Delayed Versus Immediate Cord Clamping in Preterm BirthNCT07699666 · Not applicable · Faculty of Medicine of Tunis · starts Oct 2, 2025
- Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy…NCT07687706 · Phase 3 · Hanyang University Guri Hospital · starts Jan 26, 2026
- I-FABP as a Predictor of Gastrointestinal Involvement in Pediatric IgA VasculitisNCT07664228 · Not reported · Bursa City Hospital · starts May 15, 2026
Phase 3 12 of 14
- OmeprazolePotassium-transporting ATPase inhibitor
- PantoprazolePotassium-transporting ATPase inhibitor
- EsomeprazolePotassium-transporting ATPase inhibitor
- MetoclopramideDopamine D2 receptor antagonist
- Tranexamic acidPlasminogen inhibitor
- ErythromycinBacterial 70S ribosome inhibitor
- ClopidogrelPurinergic receptor P2Y12 antagonist
- FamotidineHistamine H2 receptor antagonist
- CimetidineHistamine H2 receptor antagonist
- RabeprazolePotassium-transporting ATPase inhibitor
- AspirinCyclooxygenase inhibitor
- EpinephrineAdrenergic receptor agonist
Phase 2 1
- AzithromycinBacterial 70S ribosome inhibitor
Phase 1 or earlier 1
- OctreotideSomatostatin receptor agonist
How its trials ended
292 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 65 whose ending is known, 38% met their primary endpoint, 11% missed it and 51% stopped early.
- Completed, result not reported12041%
- Status unknown5820%
- Ongoing4917%
- Met its primary endpoint259%
- Stopped: other or unclear197%
- Stopped: enrollment or feasibility114%
- Missed its primary endpoint72%
- Stopped: sponsor or business decision21%
- Stopped: lack of efficacy1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA